2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 202

Risk of Inflammatory Arthritis Development in the Family Members of Indigenous North American (INA) RA Patients

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 218

Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 224

Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 370

Rituximab in Idiopathic Retroperitoneal Fibrosis

Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 24

Rituximab Induces an Early Re-Assessment of the Immune and Vascular Systems in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 827

Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events

Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

9:00AM-11:00AM: Abstract Number: 174

Rivaroxaban Versus Warfarin As Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome: A Randomized, Multicenter, Open-Label, Clinical Trial

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 7

RNA Sequencing Detection of Gene Dysregulation in B Cells Sorted from Salivary Gland Tissue and from Peripheral Blood Reveals New Pathways Involved in Primary Sjögren’s Syndrome Pathophysiology

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 129

Rnaseq Analysis of Human Skin in Organ Culture Identifies Collagen 22A1 As a TGF-β Early Response Gene

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 6

Ro52/Trim21 Influences Follicular B Cell Homeostasis and Immunoglobulin Production

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 413

S100A8 & S100A9: Alarmin Mediated Inflammation in Tendinopathy

Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 791

Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 360

Sarcoidosis Induced By Immune Check Point Inhibitors

Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 465

Seasonal Variation in Cutaneous Flares for Pediatric Lupus

Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

9:00AM-11:00AM: Abstract Number: 489

Self-Reported Depression in Patients with Rheumatoid Arthritis Is Undertreated and Associated with Poorer Clinical Status and Lower Rates of Remission in Routine Care

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].